
Eli Lilly and Company LLY
Annual report 2025
added 02-12-2026
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NYSESPB |
Shares |
897 M |
Market Cap[1] |
$ 891 B |
EBITDA (LTM) |
$ 2.37 B |
P/E (LTM) |
71.97 |
P/S (LTM) |
17.39 |
EPS (LTM) |
13.74 |
Eli Lilly and Company is one of the world's largest pharmaceutical companies, specializing in the development, manufacturing, and sale of innovative drugs for the treatment of various diseases.
The company was founded in 1876 in Indianapolis, Indiana and has since become a leader in the pharmaceutical industry. Eli Lilly and Company develops and manufactures a wide range of drugs, including those for diabetes, cancer, mental disorders, Alzheimer's disease, and other illnesses.
One of the company's most well-known developments is insulin, which was created in 1923. This drug became the first effective treatment for diabetes and has saved millions of lives worldwide.
Eli Lilly and Company actively invests in research and development of new drugs to help patients worldwide fight various diseases. The company also aims to improve the quality of life for patients by providing them with access to high-quality drugs. Is a global company with operations in more than 125 countries. The company cares about its employees and society as a whole, participating in various charitable projects and social responsibility programs.
Overall, is one of the most successful and innovative companies in the pharmaceutical industry. Its products help millions of people worldwide overcome difficulties associated with various diseases and improve their quality of life.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | ||
|
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | ||
|
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | ||
|
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | ||
|
BioNTech SE
BNTX
|
$ 94.95 | -0.58 % | $ 27.2 B | Nasdaq Global Select Market | ||
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
Checkmate Pharmaceuticals
CMPI
|
- | - | $ 231 M | Nasdaq Global Market | ||
|
INmune Bio
INMB
|
$ 1.53 | -0.65 % | $ 37.9 M | Nasdaq Capital Market | ||
|
ACADIA Pharmaceuticals
ACAD
|
$ 22.06 | -1.3 % | $ 3.66 B | Nasdaq Global Select Market,SPB | ||
|
Exelixis
EXEL
|
$ 48.46 | 9.1 % | $ 13.2 B | Nasdaq Global Select Market,SPB | ||
|
Fortress Biotech
FBIO
|
$ 2.56 | 3.86 % | $ 71.4 M | Nasdaq Capital Market | ||
|
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | ||
|
Esperion Therapeutics
ESPR
|
$ 3.14 | 0.87 % | $ 653 M | Nasdaq Global Market,SPB | ||
|
Can-Fite BioPharma Ltd.
CANF
|
$ 3.46 | -1.14 % | $ 5.7 M | NYSE American | ||
|
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | ||
|
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | ||
|
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | ||
|
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | ||
|
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | ||
|
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | ||
|
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | ||
|
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | ||
|
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | ||
|
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | ||
|
Arcutis Biotherapeutics
ARQT
|
$ 24.04 | 2.65 % | $ 3.06 B | Nasdaq Global Select Market,SPB | ||
|
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | ||
|
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | ||
|
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | ||
|
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | ||
|
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | ||
|
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | ||
|
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | ||
|
Aridis Pharmaceuticals
ARDS
|
- | 17.91 % | $ 11.1 M | Nasdaq Capital Market | ||
|
CRISPR Therapeutics AG
CRSP
|
$ 55.27 | 5.52 % | $ 4.97 B | Nasdaq Global Market,SPB | ||
|
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | ||
|
Autolus Therapeutics plc
AUTL
|
$ 1.72 | 4.57 % | $ 458 M | Nasdaq Global Select Market | ||
|
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | ||
|
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | ||
|
Завод ДИОД
DIOD
|
- | - | - | MOEX,SPB | ||
|
Фармсинтез
LIFE
|
- | - | - | MOEX | ||
|
AstraZeneca PLC
AZN
|
- | - | $ 96.9 B | Nasdaq Global Select Market | ||
|
Galapagos NV
GLPG
|
$ 28.81 | 1.48 % | $ 2.69 B | Nasdaq Global Select Market | ||
|
Genmab A/S
GMAB
|
$ 27.95 | 1.48 % | $ 17.2 B | Nasdaq Global Select Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.